pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,723 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1893Endpoints1466Fierce Biotech779BioSpace767BioPharma Dive555raps257onclive165fda recalls
therapy area
allOncology13097Rare Disease3399Immunology3069Cardiology2869Hematology2336Pulmonology2300Vaccines
  • PepGen reports promising early results for myotonic dystrophy type 1 drug in six-patient trial
    PepGen announced that its experimental therapy for myotonic dystrophy type 1 showed the most encouraging early data yet in a small study. The trial involved six patients who received the drug for 1…
    STAT · 10d agoPositive readoutPositive↗ source
  • Democratic wins in Texas, Georgia and Wisconsin could open Medicaid expansion for over a million residents
    Three of the ten states that have not yet expanded Medicaid may revisit their stance after recent Democratic gains in state elections. Texas, Georgia and Wisconsin saw power shifts that could make…
    STAT · 11d agoRegulatoryNeutral↗ source
← prev
page 10 of 149
next →
126
fda medwatch117
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Senators Wyden and Sanders unite on push to lower Medicare eligibility age by a decade
    Senate Finance Committee Chair Ron Wyden (D-Ore.) and Independent Senator Bernie Sanders (I-Vt.) said they are aligned on advancing a “Medicare for All” agenda. Sanders has proposed lowering the M…
    STAT · 10d agoRegulatoryNeutral↗ source
  • Laub’s Feeding & Cubing voluntarily recalls 89 tons of mini hay cubes over botulism risk
    Laub’s Feeding & Cubing, Inc. of Beryl, Utah announced a voluntary recall of its Grade A Mini Hay Cubes. The recall covers up to 89 tons of product sold between Oct 3 and Oct 31, 2026 after the co…
    fda recalls · 11d agoCRLNegative↗ source
  • Flu season this year appears to be affecting teens and young adults more severely, experts say
    The article notes that flu activity this year has already resulted in at least 1.7 million reported cases, and health experts are observing that teenagers and young adults are experiencing higher r…
    STAT · 10d agoNeutral↗ source
  • Experts warn AI health advice may be accurate yet lead to poorer outcomes
    Artificial intelligence now answers hundreds of millions of health questions each week, with tools like ChatGPT fielding queries from the public at an unprecedented scale. Government officials and…
    STAT · 11d agoNegative↗ source
  • OpenAI’s health chief envisions ChatGPT Health moving patients from answers to actionable steps
    Nate Gross, who leads the health division at OpenAI, spoke at an Endpoints News health briefing about the company’s next steps for its AI health offering. He said the goal is to evolve ChatGPT Hea…
    Endpoints · 10d agoPositive↗ source
  • Men turn to chatbots for therapy as earnings season unfolds
    The latest STAT Health Tech newsletter notes growing optimism about mental‑health chatbots, especially among men who are less likely to seek traditional therapy. It also recaps key points from the…
    STAT · 10d agoNeutral↗ source
  • HHS Secretary RFK Jr. stays optimistic about Make America Healthy Again initiative despite midterm setbacks
    HHS Secretary Robert F. Kennedy Jr., who leads the Make America Healthy Again (MAHA) effort, addressed lawmakers on Capitol Hill this week. Throughout the year, industry observers have debated his…
    Endpoints · 10d agoPositive↗ source
  • Employers and consumers poised to reshape healthcare, says Health Tech Day discussion
    Last week the organizers held their second Health Tech Day, featuring an in‑person happy hour in New York and a live virtual stream for remote attendees. The forum focused on how employers and con…
    Endpoints · 10d agoNeutral↗ source
  • Family Farmstead Dairy recalls all cheddar cheese over possible Listeria contamination
    Family Farmstead Dairy announced a recall of all its cheddar cheese products because they may be contaminated with Listeria monocytogenes. Listeria can cause serious infections, especially in youn…
    fda recalls · 11d agoRegulatoryNegative↗ source
  • Oura to buy AI care startup Counsel Health for $625M
    Wearable ringmaker Oura is buying AI primary care startup Counsel Health. Oura is paying $625 million in cash for Counsel, which offers medical AI services as well as virtual visits with doctors. T…
    Endpoints · 10d ago↗ source
  • STAT+: GLP-1s are given an FDA warning for rare eye condition risk
    The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”
    STAT · 10d ago↗ source
  • FDA approves Bayer’s Sunharbo, first Factor XIa inhibitor to lower stroke recurrence risk
    The Food and Drug Administration has approved Bayer's new medication intended to prevent another stroke in patients who have already experienced one. The drug, sold under the brand name Sunharbo,…
    STAT · 11d agoApprovalPositive↗ source
  • FDA warns GLP-1 weight-loss drugs may cause rare eye stroke condition
    The Food and Drug Administration issued a warning that GLP-1 drugs used for weight loss may be linked to a rare eye condition called non-arteritic anterior ischemic optic neuropathy, sometimes desc…
    STAT · 11d agoRegulatoryNegative↗ source
  • New evidence links gene‑therapy viral vectors to tumor formation in pediatric patients
    For years, scientists have debated whether the viral vectors used in gene therapy could cause cancer. Recent case reports now provide strong evidence that such a risk is real. The reports involve…
    STAT · 11d agoNegative readoutNegative↗ source
  • Third Rock Ventures commits up to $2.16 billion to AI-driven Chinese biotech Funnel Biosciences
    Third Rock Ventures disclosed a partnership with Chinese biotech Funnel Biosciences, committing up to $2.16 billion to support its AI-driven biologics platform. The agreement includes a research c…
    Endpoints · 11d agoDealPositive↗ source
  • Democrats’ Midterm Wins Boost Hospital Prospects as CVS Breakup Looms
    Voters gave Democrats a decisive edge in the recent midterm elections, reshaping the political landscape for the coming year. The shift is expected to favor the hospital sector, which stands to gai…
    STAT · 11d agoPositive↗ source
  • Delix Therapeutics secures $100 million Series C to advance psychedelic pipeline
    Delix Therapeutics announced it has closed a $100 million Series C financing round. The capital will be used to accelerate development of its pipeline of psychedelic and neuroplastogen candidates…
    Endpoints · 11d agoDealPositive↗ source
  • Boehringer Ingelheim to seek approval for obesity injection survodutide after trial shows no added cardiovascular risk
    Boehringer Ingelheim announced it will file for regulatory approval of its investigational GLP-1 based obesity injection, survodutide, in the coming year. The move follows a phase 3 trial that dem…
    Endpoints · 11d agoApprovalNeutral↗ source
  • Eli Lilly to pursue FDA approval for obesity drug in obstructive sleep apnea after positive Phase 3 trial
    Eli Lilly announced that it will seek regulatory approval for its obesity medication as a treatment for obstructive sleep apnea, following a successful Phase 3 study. The trial showed positive res…
    Endpoints · 11d agoPositive readoutPositive↗ source
  • Lilly's oral GLP-1 pill Foundayo reduces sleep apnea events in late-stage trials
    In two late-stage trials, Eli Lilly’s oral GLP‑1 pill Foundayo lowered the apnea‑hypopnea index by an average of 17.8 events per hour, compared with a 4.5‑event reduction for patients on placebo.…
    STAT · 11d agoPositive readoutPositive↗ source
  • Marea Therapeutics' triglyceride drug lowers levels without raising blood sugar in high-risk patients
    Marea Therapeutics reported new data on its investigational lipid‑lowering medicine, showing it can further reduce triglyceride levels in patients with dangerously high blood concentrations. The s…
    Endpoints · 11d agoPositive readoutPositive↗ source
  • Argenx to acquire macrocycle biotech Unnatural Products in up to $1.15 billion deal
    Argenx announced Monday it will acquire Unnatural Products, a biotech focused on macrocycle therapeutics that began as a garage startup. The transaction is structured as an up-to-$1.15 billion dea…
    Endpoints · 11d agoDealNeutral↗ source
  • Democrats weigh limits of health-care reforms after midterm win
    In the days after their sweeping midterm victories, House and Senate Democrats are debating the scope of possible health-care actions. Party leaders agree on rolling back the Medicaid cuts impleme…
    STAT · 12d agoRegulatoryNeutral↗ source